A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors

Clinical Cancer Research

Volumn 19, Issue 1, 2013, Pages 268-278

  Jameson, Gayle S ^a   Hamm, John T ^c   Weiss, Glen J ^a   Alemany, Carlos ^d   Anthony, Stephen ^a   Basche, Michele ^e   Ramanathan, Ramesh K ^a   Borad, Mitesh J ^b   Tibes, Raoul ^b   Cohn, Allen ^e   Hinshaw, Ioana ^e   Jotte, Robert ^e   Rosen, Lee S ^f   Hoch, Ute ^g   Eldon, Michael A ^g   Medve, Robert ^g   Schroeder, Katrina ^a   White, Erica ^a   Von Hoff, Daniel D ^a  

^a HonorHealth Research Institute   (United States)

^b MAYO CLINIC   (United States)

^c Norton Healthcare   (United States)

^d Cancer Center   (United States)

^e ROCKY MOUNTAIN CANCER CENTERS   (United States)

^f Premiere Oncology   (United States)

^g NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRINOTECAN PEGOL; FIRTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLURRED VISION; BREAST CANCER; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OVARY CANCER; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

EID: 84871993895     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1201     Document Type: Article

References (30)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev 2006;6:789-802.
2. Persson H, Antonian L, Staschen C-M, Viegas T, Bentley M. Polyethylene glycol conjugation of irinotecan improves its antitumor activity in three mouse xenograft models. Proc Am Assoc Cancer Res 2007:259. Abstract C10.
3. Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996;32A(suppl 3):S13-7.
4. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996;23(1 suppl 3):21-6.
5. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999;35:371-9.
6. Pizzolato JF, Saltz LB. Irinotecan (Campto) in the treatment of pancreatic cancer. Expert Rev Anticancer Ther 2003;3:587-93.
7. Von Hoff D. Future directions for the clinical research with CPT-11 (irinotecan). Eur J Cancer 1996;32A(suppl 3):S9-12.
8. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
9. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
10. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95.
11. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 2000;6:3451-8.
12. Eldon MA, Staschen CM, Viegas T, et al.: NKTR-102, a novel PEGylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN-38 exposure. Proc Am Assoc Cancer Res 2007:306. Abstract C157.
13. World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, October 2008. Available at: www.wma.net/en/30publications/10policies/b3/index.html. Accessed March 8, 2012.
14. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002;20:3293-301.
17. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, et al. Irinotecan (CPT-11) high-dose escalation using intensive highdose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9.
18. Michael M, Brittain MA, Nagai J, Feld R, Hedley D, Oza A, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004;22:4410-7.
19. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003;1:35-46.
20. Schmittel A, Jahnke K, Thiel E, Keilholz U. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol 2004;15:1296.
21. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, et al. Modulation of Irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Can Res 2001;7:1136-41.
22. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, Herrera L, Creaven P. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993;72:1543-6.
23. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002;72:265-75.
24. Burris HA III, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816-20.
25. Supko JG, Plowman J, Dykes DJ, Zaharko DS. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 1992;33:432.
26. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
27. Furuta T, Yokokura T. Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 1990;17:121-30.
28. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010;330:831.
29. Vergote IB, Micha JP, Pippitt CH Jr, Rao GG, Spitz DL, Reed N, et al. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. J Clin Oncol 2010;28(15s):393s. Abstract 5013.
30. Awada A, Chan S, Jerusalem G, Huizing M, Coleman RE, Mehdi A, et al. Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of irinotecan, in patients with pre-treated metastatic breast cancer (MBC). Presented at: 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 12, 2010; San Antonio, TX. Abstract P6-11-01.